HomeLSTA • NASDAQ
add
Lisata Therapeutics Inc
Previous close
$2.47
Day range
$2.31 - $2.53
Year range
$1.87 - $4.20
Market cap
21.81M USD
Avg Volume
11.54K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | 1.00M | — |
Operating expense | 5.95M | -1.26% |
Net income | -4.61M | 14.07% |
Net profit margin | -461.00 | — |
Earnings per share | -0.55 | 16.67% |
EBITDA | -4.91M | 17.90% |
Effective tax rate | 0.00% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 31.24M | -38.17% |
Total assets | 35.00M | -36.00% |
Total liabilities | 5.68M | -16.40% |
Total equity | 29.32M | — |
Shares outstanding | 27.70M | — |
Price to book | 0.70 | — |
Return on assets | -33.80% | — |
Return on capital | -39.23% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | -4.61M | 14.07% |
Cash from operations | -4.53M | -11.28% |
Cash from investing | 1.39M | 124.31% |
Cash from financing | -96.00K | -500.00% |
Net change in cash | -3.30M | 66.45% |
Free cash flow | -2.95M | -25.90% |
About
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
Founded
1980
Headquarters
Website
Employees
26
